NB
MCID: NRB001
MIFTS: 62

Neuroblastoma (NB)

Categories: Cancer diseases, Endocrine diseases, Eye diseases, Fetal diseases, Gastrointestinal diseases, Genetic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Neuroblastoma

MalaCards integrated aliases for Neuroblastoma:

Name: Neuroblastoma 11 19 42 58 75 28 5 41 43 14 38 16 71
Nb 19 42
Neuroblastoma, Susceptibility to 28
Central Neuroblastoma 71
Neuroblastomas 14

Characteristics:


Prevelance:

1-5/10000 (Europe, Germany) 1-9/100000 (United States) 58

Age Of Onset:

Childhood 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:769
MeSH 43 D009447
NCIt 49 C3270
SNOMED-CT 68 432328008
MESH via Orphanet 44 C536408 D009447
ICD10 via Orphanet 32 C74.9
UMLS via Orphanet 72 C0027819 C2931189
Orphanet 58 ORPHA635
SNOMED-CT via HPO 69 126950007
UMLS 71 C0027819 C0700095

Summaries for Neuroblastoma

MedlinePlus: 41 What is neuroblastoma? Neuroblastoma is a type of cancer that forms in nerve cells called neuroblasts. Neuroblasts are immature nerve tissue. They normally turn into working nerve cells. But in neuroblastoma, they form a tumor. Neuroblastoma usually begins in the adrenal glands. You have two adrenal glands, one on top of each kidney. The adrenal glands make important hormones that help control heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Neuroblastoma may also begin in the neck, chest or spinal cord. What causes neuroblastoma? Neuroblastoma is caused by mutations (changes) in genes. In most cases, the cause of the mutation is unknown. In some other cases, the mutation is passed from the parent to the child. What are the symptoms of neuroblastoma? Neuroblastoma often begins in early childhood. Sometimes it begins before a child is born.The most common symptoms are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone.They include: A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part (paralysis) How is neuroblastoma diagnosed? To diagnose neuroblastoma, your child's health care provider will do various tests and procedures, which may include: A medical history A neurological exam Imaging tests, such as x-rays, a CT scan, an ultrasound, an MRI, or an MIBG scan. In an MIBG scan, a small amount of a radioactive substance is injected into a vein. It travels through the bloodstream and attaches itself to any neuroblastoma cells. A scanner detects the cells. Blood and urine tests Biopsy, where a sample of tissue is removed and examined under a microscope Bone marrow aspiration and biopsy, where bone marrow, blood, and a small piece of bone are removed for testing What are the treatments for neuroblastoma? The treatments for neuroblastoma include: Observation, also called watchful waiting, where the health care provider does not give any treatments until your child's signs or symptoms appear or change Surgery Radiation therapy Chemotherapy High-dose chemotherapy and radiation therapy with stem cell rescue. Your child will get high doses of chemotherapy and radiation. This kills the cancer cells, but it also kills healthy cells. So your child will get a stem cell transplant, usually of his or her own cells collected earlier. This helps to replace the healthy cells that were lost. Iodine 131-MIBG therapy, a treatment with radioactive iodine. The radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells NIH: National Cancer Institute

MalaCards based summary: Neuroblastoma, also known as nb, is related to differentiating neuroblastoma and glioma, and has symptoms including tremor, back pain and headache. An important gene associated with Neuroblastoma is ALK (ALK Receptor Tyrosine Kinase). The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, bone marrow and spinal cord, and related phenotypes are neoplasm of the nervous system and elevated urinary catecholamines

MedlinePlus Genetics: 42 Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. Most commonly, the tumor originates in the nerve tissue of the adrenal gland located above each kidney. Other common sites for tumors to form include the nerve tissue in the abdomen, chest, neck, or pelvis. Neuroblastoma can spread (metastasize) to other parts of the body such as the bones, liver, or skin.Individuals with neuroblastoma may develop general signs and symptoms such as irritability, fever, tiredness (fatigue), pain, loss of appetite, weight loss, or diarrhea. More specific signs and symptoms depend on the location of the tumor and where it has spread. A tumor in the abdomen can cause abdominal swelling. A tumor in the chest may lead to difficulty breathing. A tumor in the neck can cause nerve damage known as Horner syndrome, which leads to drooping eyelids, small pupils, decreased sweating, and red skin. Tumor metastasis to the bone can cause bone pain, bruises, pale skin, or dark circles around the eyes. Tumors in the backbone can press on the spinal cord and cause weakness, numbness, or paralysis in the arms or legs. A rash of bluish or purplish bumps that look like blueberries indicates that the neuroblastoma has spread to the skin.In addition, neuroblastoma tumors can release hormones that may cause other signs and symptoms such as high blood pressure, rapid heartbeat, flushing of the skin, and sweating. In rare instances, individuals with neuroblastoma may develop opsoclonus myoclonus syndrome, which causes rapid eye movements and jerky muscle motions. This condition occurs when the immune system malfunctions and attacks nerve tissue.Neuroblastoma occurs most often in children before age 5 and rarely occurs in adults.

GARD: 19 Neuroblastoma is a tumor that develops from neuroblasts (immature nerve tissue) in an infant or child, usually before the age of 5. It most often develops in infancy and may be diagnosed in the first month of life. The tumor most often develops in the adrenal gland, but may develop in the neck, chest, or spinal cord. It is considered an aggressive tumor because it often spreads to other parts of the body (metastasizes). In most cases, it has spread by the time it is diagnosed. A Neuroblastoma can cause a variety of signs and symptoms, including a lump where the tumor is growing, bone pain, diarrhea, and various neurological symptoms. The cause of most Neuroblastomas is not known. Rarely, a Neuroblastoma is caused by an inherited genetic change in a gene, such as the ALK gene or PHOX2B gene. Diagnosing a Neuroblastoma may rely on a physical examination, blood tests, imaging tests (such as MRI or CT scan) and ultimately, a biopsy.

Orphanet: 58 Neuroblastoma is a malignant tumor of neural crest cells, the cells that give rise to the sympathetic nervous system, which is observed in children.

Disease Ontology: 11 An autonomic nervous system neoplasm that derives from immature nerve cells.

Wikipedia: 75 Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently... more...

Related Diseases for Neuroblastoma

Diseases in the Neuroblastoma family:

Neuroblastoma 1 Neuroblastoma 2
Neuroblastoma 3 Neuroblastoma 4
Neuroblastoma 5 Neuroblastoma 6
Neuroblastoma 7

Diseases related to Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1475)
# Related Disease Score Top Affiliating Genes
1 differentiating neuroblastoma 32.4 NBAT1 MYCNUT
2 glioma 31.2 MIR34A MIR184 MIR17 MEG3 MALAT1 HOTAIR
3 medulloblastoma 31.1 MYCNOS MIR34A MIR17 HOTAIR H19 ALK
4 glioblastoma 31.0 MYCNOS MIR34A MEG3 MALAT1 HOTAIR H19
5 osteogenic sarcoma 30.6 SNHG1 MEG3 MALAT1 HOTAIR H19 GAS5
6 b-cell lymphoma 30.6 MIR17 MALAT1 HOTAIR GAS5 ALK
7 leukemia, acute myeloid 30.5 MIR34A MIR184 MIR17 MEG3 MALAT1 HOTAIR
8 thyroid carcinoma 30.5 MALAT1 HOTAIR H19 GAS5
9 melanoma 30.4 PAUPAR MIR34A MIR184 MIR17 MEG3 MALAT1
10 renal cell carcinoma, nonpapillary 30.4 NBAT1 MIR34A MIR17 MEG3 MALAT1 HOTAIR
11 pituitary adenoma 30.3 MEG3 MALAT1 HOTAIR H19
12 leukemia, chronic myeloid 30.2 MIR17 MEG3 HOTAIR H19 ALK
13 lung cancer susceptibility 3 30.1 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
14 thyroid cancer, nonmedullary, 1 30.0 MEG3 MALAT1 HOTAIR H19
15 high grade glioma 30.0 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
16 nasopharyngeal carcinoma 30.0 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
17 mantle cell lymphoma 30.0 MIR17 MALAT1 GAS5 ALK
18 bladder cancer 29.9 SNHG16 MIR17 MEG3 MALAT1 HOTAIR HAGLR
19 ovarian cancer 29.9 SNHG16 NBAT1 MIR34A MIR17 MEG3 MALAT1
20 kidney cancer 29.7 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
21 myeloma, multiple 29.7 MIR17 MEG3 MALAT1 HOTAIR H19 GAS5
22 tongue squamous cell carcinoma 29.5 MIR184 MIR17 MEG3 MALAT1
23 liver cirrhosis 29.4 MEG3 MALAT1 HOTAIR GAS5
24 gastric cancer 29.4 SNHG8 SNHG16 SNHG1 MIR34A MIR17 MEG3
25 hepatocellular carcinoma 29.0 SNHG1 MIR34A MIR17 MEG3 MALAT1 HOTAIR
26 neuroblastoma 1 11.6
27 olfactory neuroblastoma 11.6
28 neuroblastoma 2 11.6
29 adrenal neuroblastoma 11.4
30 cns neuroblastoma with foxr2 activation 11.4
31 cerebral neuroblastoma 11.3
32 neuroblastoma 3 11.3
33 cervical neuroblastoma 11.3
34 retinoblastoma 11.3
35 nasal cavity olfactory neuroblastoma 11.2
36 spinal cord neuroblastoma 11.2
37 neuroblastoma 4 11.2
38 neuroblastoma 5 11.2
39 extracranial neuroblastoma 11.2
40 neuroblastoma 6 11.1
41 retroperitoneal neuroblastoma 11.1
42 ganglioneuroblastoma 11.1
43 ewing sarcoma 11.1
44 central nervous system neuroblastoma 11.1
45 neuroblastoma 7 11.1
46 adrenal carcinoma 11.1
47 weaver syndrome 11.1
48 simpson-golabi-behmel syndrome, type 1 11.0
49 chylothorax, congenital 11.0
50 mediastinum neuroblastoma 11.0

Graphical network of the top 20 diseases related to Neuroblastoma:



Diseases related to Neuroblastoma

Symptoms & Phenotypes for Neuroblastoma

Human phenotypes related to Neuroblastoma:

58 30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the nervous system 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004375
2 elevated urinary catecholamines 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011976

UMLS symptoms related to Neuroblastoma:


tremor; back pain; headache; syncope; pain; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness

Drugs & Therapeutics for Neuroblastoma

Drugs for Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
4
Dinutuximab Approved, Investigational Phase 4 1363687-32-4
5
Sargramostim Approved, Investigational Phase 4 123774-72-1
6
Topotecan Approved, Investigational Phase 4 123948-87-8, 119413-54-6 60699 60700
7
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
8
Irinotecan Approved, Investigational Phase 4 97682-44-5, 100286-90-6 60838
9
Temozolomide Approved, Investigational Phase 4 85622-93-1 5394
10
Molgramostim Investigational Phase 4 99283-10-0
11 Adjuvants, Immunologic Phase 4
12 Hormones Phase 4
13 Hormone Antagonists Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16
Hydroxyitraconazole Phase 4 108222
17 Immunologic Factors Phase 4
18 Antirheumatic Agents Phase 4
19 Alkylating Agents Phase 4
20 Antineoplastic Agents, Alkylating Phase 4
21 topoisomerase I inhibitors Phase 4
22 Immunosuppressive Agents Phase 4
23
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
24
Carbamide peroxide Approved Phase 2, Phase 3 124-43-6
25
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
26
Dacarbazine Approved, Investigational Phase 3 4342-03-4 2942 5351166
27
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
28
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
29
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
30
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
31
Rituximab Approved Phase 3 174722-31-7
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
34
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
35
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
36
Ethinylestradiol Approved Phase 3 57-63-6 5991
37
Polyestradiol phosphate Approved Phase 3 28014-46-2
38
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
39
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8 5280382 445354
41 Radiopharmaceuticals Phase 3
42 3-Iodobenzylguanidine Phase 3
43 Antitubercular Agents Phase 3
44 Calcium, Dietary Phase 3
45
Sodium thiosulfate Phase 3
46 Antioxidants Phase 3
47 Cardiotonic Agents Phase 3
48
Razoxane Phase 3
49 Dihydroxyphenylalanine Phase 3
50 Iron-Dextran Complex Phase 3

Interventional clinical trials:

(show top 50) (show all 540)
# Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
2 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
3 RAPID Feasibility Study: A Pilot Study for the Rapid Infusion of Dinutuximab Not yet recruiting NCT05421897 Phase 4 Dinutuximab with Chemotherapy
4 European Infant Neuroblastoma Study Final Protocol Unknown status NCT00417053 Phase 3 busulfan;carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide phosphate;melphalan;vincristine sulfate
5 NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma Unknown status NCT00410631 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate;vindesine
6 UKCCSG Stage IIB/3 (INSS) Neuroblastoma Pilot Study [ENSG VI (Pilot 2B/3)] Unknown status NCT00416676 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
7 High Risk Neuroblastoma Study 1 Of Siop-Europe Unknown status NCT00030719 Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;isotretinoin;melphalan;vincristine sulfate
8 Randomized Study of Radiotherapy in Patients With Stage 2B/3 (INSS) Neuroblastoma in Children Over 1 Year of Age Unknown status NCT00276731 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
9 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
10 Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma Completed NCT00567567 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate Liposome
11 Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma Completed NCT00499616 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride;Isotretinoin;Filgrastim
12 Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma Completed NCT03042429 Phase 3 Cycles N8, N5 and N6;Cycles N5 and N6
13 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
14 Treatment Of Children Over The Age Of 1 Year With Unresectable Localized Neuroblastoma Without MYCN Amplification Completed NCT00025428 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
15 Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study Completed NCT00003093 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
16 PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS Completed NCT00002802 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;mesna;vincristine sulfate;vindesine
17 Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year Completed NCT00365755 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;melphalan;vincristine sulfate
18 A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma Completed NCT00004188 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate
19 A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy Completed NCT01041638 Phase 3 Isotretinoin
20 Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study Completed NCT00003119 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
21 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
22 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
23 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Completed NCT03042416 Phase 3 18F-DOPA
24 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
25 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
26 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide
27 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Recruiting NCT04221035 Phase 3 Vincristine;Carboplatin;Etoposide;Cyclophosphamide;Vindesine;Dacarbazine;Ifosfamide;Doxorubicin;Busulfan;Melphalan;Thiotepa;Dinutuximab Beta;Cisplatin
28 A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Recruiting NCT03275402 Phase 2, Phase 3
29 A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma Recruiting NCT04724369 Phase 3 18F-MFBG
30 High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) Recruiting NCT01704716 Phase 3 Vincristine;Aldesleukin;ch14.18/CHO;Carboplatin;Etoposide;Cisplatin;Cyclophosphamide;Doxorubicin;G-CSF;Busulfan;Melphalan
31 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) Recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Cyclophosphamide;Dexrazoxane Hydrochloride;Doxorubicin Hydrochloride;Etoposide Phosphate;Isotretinoin;Lorlatinib;Melphalan Hydrochloride;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate
32 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
33 18F-DOPA II - PET Imaging Optimization Recruiting NCT04706910 Phase 3 18F-DOPA;Furosemide Injection
34 Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue Active, not recruiting NCT00026312 Phase 3 Isotretinoin
35 A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone Active, not recruiting NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
36 Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome Active, not recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
37 Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma Terminated NCT00539500 Phase 2, Phase 3 Carboplatin;Etoposide;Melphalan
38 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Terminated NCT01987596 Phase 3
39 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
40 An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)] Unknown status NCT00392340 Phase 2 doxorubicin hydrochloride;topotecan hydrochloride;vincristine sulfate
41 Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study Unknown status NCT02173093 Phase 1, Phase 2
42 Evaluation of Benefit and Side Effects of 131I-MIBG in Combination With Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma Unknown status NCT00798148 Phase 1, Phase 2 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation
43 A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma Unknown status NCT01701479 Phase 1, Phase 2 ch14.18/CHO;Aldesleukin;Isotretinoin
44 Phase 2 Study of Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma Unknown status NCT02615106 Phase 2 Endostar
45 Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma Unknown status NCT02258815 Phase 2 ch14.18/CHO
46 High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma Unknown status NCT03061656 Phase 2 Cyclophosphamide;Carboplatin;Etoposide;Thiotepa;Melphalan
47 Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma Unknown status NCT00416559 Phase 2
48 Pilot Study of Anti-GD2 and Expanded, Activated Natural Killer Cell Infusion for Neuroblastoma Unknown status NCT03242603 Phase 1, Phase 2
49 A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis Unknown status NCT00024193 Phase 2 busulfan;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
50 Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma Unknown status NCT00003122 Phase 2

Search NIH Clinical Center for Neuroblastoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Etoposide
etoposide phosphate
Isotretinoin
Melphalan
Melphalan hydrochloride
Vincristine
Vincristine Sulfate

Cochrane evidence based reviews: neuroblastoma

Genetic Tests for Neuroblastoma

Genetic tests related to Neuroblastoma:

# Genetic test Affiliating Genes
1 Neuroblastoma 28
2 Neuroblastoma, Susceptibility to 28

Anatomical Context for Neuroblastoma

Organs/tissues related to Neuroblastoma:

MalaCards : Adrenal Gland, Bone Marrow, Spinal Cord, Bone, T Cells, Skin, Thyroid

Publications for Neuroblastoma

Articles related to Neuroblastoma:

(show top 50) (show all 31422)
# Title Authors PMID Year
1
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 62 5
21948233 2011
2
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. 62 5
21838707 2011
3
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. 62 5
22072639 2011
4
The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. 62 5
21242967 2011
5
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. 62 5
18990089 2008
6
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. 62 5
18923523 2008
7
Activating mutations in ALK provide a therapeutic target in neuroblastoma. 62 5
18923525 2008
8
Identification of ALK as a major familial neuroblastoma predisposition gene. 62 5
18724359 2008
9
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. 62 5
18334619 2008
10
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies. 62 41
36460335 2022
11
The human ion channel TRPM2 modulates migration and invasion in neuroblastoma through regulation of integrin expression. 62 41
36446940 2022
12
Benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide induces ferroptosis in neuroblastoma cells through redox imbalance. 62 41
36450496 2022
13
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
14
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. 5
21575866 2011
15
MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. 62 46
20841484 2010
16
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. 62 46
19584290 2009
17
Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3' untranslated region: a role for microRNA23b. 62 46
18716031 2008
18
The MYCN oncogene is a direct target of miR-34a. 62 46
18504438 2008
19
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. 62 46
18493594 2008
20
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. 62 46
18505919 2008
21
MYCN regulates oncogenic MicroRNAs in neuroblastoma. 62 46
17943719 2008
22
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. 62 46
17297439 2007
23
The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. 62 46
17483472 2007
24
Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. 62 46
17283129 2007
25
Valproate-induced hepatoxicity: protective effect of L-carnitine supplementation. 5
2124297 1990
26
Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells. 62
36453406 2023
27
The alteration of the expression level of neuropathy target esterase in human neuroblastoma SK-N-SH cells disrupts cellular phospholipids homeostasis. 62
36336212 2023
28
Hydrothermal vs microwave nanoarchitechtonics of carbon dots significantly affects the structure, physicochemical properties, and anti-cancer activity against a specific neuroblastoma cell line. 62
36244103 2023
29
Cost-effectiveness of childhood cancer treatment in Egypt: Lessons to promote high-value care in a resource-limited setting based on real-world evidence. 62
36386036 2023
30
CFDP1 is a neuroblastoma susceptibility gene that regulates transcription factors of the noradrenergic cell identity. 62
36425957 2023
31
Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy. 62
36129239 2023
32
Primary Olfactory Neuroblastoma of the Nasopharynx: A Case Report. 62
33474978 2023
33
Immunotherapy with anti-GD2 monoclonal antibody in infants with high-risk neuroblastoma. 62
35913764 2023
34
Quercetin Attenuates Copper-Induced Apoptotic Cell Death and Endoplasmic Reticulum Stress in SH-SY5Y Cells by Autophagic Modulation. 62
35149956 2022
35
The role of ADC value and Ki-67 index in predicting the response to neoadjuvant chemotherapy in advanced stages of olfactory neuroblastoma. 62
36240450 2022
36
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. 62
35839426 2022
37
Celastrol promotes apoptotic cell death in children neuroblastoma cells through caspases dependent pathway. 62
36378044 2022
38
Depletion of Foxp3+ regulatory T cells but not the absence of CD19+IL-10+ regulatory B cells hinders tumor growth in a para-orthotopic neuroblastoma mouse model. 62
36054664 2022
39
Neuroblastoma SH-SY5Y Cell Differentiation to Mature Neuron by AM580 Treatment. 62
36066699 2022
40
Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma. 62
36162447 2022
41
Neuroblastoma Suppressor of Tumorigenicity 1 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension Related to Congenital Heart Disease. 62
36169661 2022
42
Metastatic neuroblastoma masquerading as orbital retinoblastoma. 62
36469584 2022
43
PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma. 62
36029394 2022
44
Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020. 62
36458672 2022
45
A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma. 62
36149505 2022
46
Transcriptome Analysis Reveals the Anti-Tumor Mechanism of Eucalyptol Treatment on Neuroblastoma Cell Line SH-SY5Y. 62
36331666 2022
47
Correction to: Transcriptome Analysis Reveals the Anti-Tumor Mechanism of Eucalyptol Treatment on Neuroblastoma Cell Line SH-SY5Y. 62
36414918 2022
48
Observation of α-Synuclein Preformed Fibrils Interacting with SH-SY5Y Neuroblastoma Cell Membranes Using Scanning Ion Conductance Microscopy. 62
36455298 2022
49
Chlorpyrifos and parathion regulate oxidative stress differentially through the expression of paraoxonase 2 in human neuroblastoma cell. 62
36058312 2022
50
Retraction Note: Fluoxetine induces apoptosis through endoplasmic reticulum stress via mitogen-activated protein kinase activation and histone hyperacetylation in SK-N-BE(2)-M17 human neuroblastoma cells. 62
36180606 2022

Variations for Neuroblastoma

ClinVar genetic disease variations for Neuroblastoma:

5 (show top 50) (show all 293)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RBM15, LOC112577475 NM_022768.5(RBM15):c.1912C>A (p.Gln638Lys) SNV Other
438785 rs1553224979 GRCh37: 1:110883939-110883939
GRCh38: 1:110341317-110341317
2 NTRK2 NM_006180.6(NTRK2):c.970T>A (p.Leu324Met) SNV Other
438780 rs201362502 GRCh37: 9:87342685-87342685
GRCh38: 9:84727770-84727770
3 MAP2K7 NM_145185.4(MAP2K7):c.752T>C (p.Leu251Pro) SNV Other
438771 rs1555701191 GRCh37: 19:7975941-7975941
GRCh38: 19:7911056-7911056
4 MET NM_000245.4(MET):c.985C>A (p.Leu329Ile) SNV Other
438775 rs1554378983 GRCh37: 7:116340123-116340123
GRCh38: 7:116700069-116700069
5 PHF6 NM_001015877.2(PHF6):c.119C>A (p.Ala40Glu) SNV Other
438782 rs1556013242 GRCh37: X:133511766-133511766
GRCh38: X:134377736-134377736
6 MAP2K4 NM_003010.4(MAP2K4):c.538C>G (p.Leu180Val) SNV Other
438770 rs1555550018 GRCh37: 17:12011131-12011131
GRCh38: 17:12107814-12107814
7 FGFR3 NM_000142.5(FGFR3):c.991T>C (p.Phe331Leu) SNV Other
438762 rs1246952737 GRCh37: 4:1805479-1805479
GRCh38: 4:1803752-1803752
8 BRCA2 NM_000059.4(BRCA2):c.1075G>A (p.Glu359Lys) SNV Other
438754 rs1555281730 GRCh37: 13:32906690-32906690
GRCh38: 13:32332553-32332553
9 TSC2 NM_000548.5(TSC2):c.3284+1G>T SNV Other
438793 rs45517289 GRCh37: 16:2129430-2129430
GRCh38: 16:2079429-2079429
10 ALK NM_004304.5(ALK):c.3522C>A (p.Phe1174Leu) SNV Pathogenic
217851 rs863225281 GRCh37: 2:29443695-29443695
GRCh38: 2:29220829-29220829
11 ALK NM_004304.5(ALK):c.3271G>A (p.Asp1091Asn) SNV Pathogenic
218628 rs864309584 GRCh37: 2:29446296-29446296
GRCh38: 2:29223430-29223430
12 ALK NM_004304.5(ALK):c.3734T>G (p.Phe1245Cys) SNV Pathogenic
217856 rs863225283 GRCh37: 2:29436859-29436859
GRCh38: 2:29213993-29213993
13 ALK NM_004304.5(ALK):c.3733T>G (p.Phe1245Val) SNV Pathogenic
65671 rs281864720 GRCh37: 2:29436860-29436860
GRCh38: 2:29213994-29213994
14 ALK NM_004304.5(ALK):c.3520T>G (p.Phe1174Val) SNV Pathogenic
65670 rs281864719 GRCh37: 2:29443697-29443697
GRCh38: 2:29220831-29220831
15 ALK NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) SNV Pathogenic
18083 rs113994087 GRCh37: 2:29432664-29432664
GRCh38: 2:29209798-29209798
16 ALK NM_004304.5(ALK):c.3452C>T (p.Thr1151Met) SNV Pathogenic
18086 rs113994091 GRCh37: 2:29445273-29445273
GRCh38: 2:29222407-29222407
17 ALK NM_004304.5(ALK):c.3521T>G (p.Phe1174Cys) SNV Pathogenic
375887 rs1057519697 GRCh37: 2:29443696-29443696
GRCh38: 2:29220830-29220830
18 ALK NM_004304.5(ALK):c.3512T>A (p.Ile1171Asn) SNV Pathogenic
375888 rs1057519698 GRCh37: 2:29445213-29445213
GRCh38: 2:29222347-29222347
19 ALK NM_004304.5(ALK):c.3512T>C (p.Ile1171Thr) SNV Pathogenic
545115 rs1057519698 GRCh37: 2:29445213-29445213
GRCh38: 2:29222347-29222347
20 ALK NM_004304.5(ALK):c.3520T>A (p.Phe1174Ile) SNV Pathogenic
217850 rs281864719 GRCh37: 2:29443697-29443697
GRCh38: 2:29220831-29220831
21 ALK NM_004304.5(ALK):c.3833A>C (p.Tyr1278Ser) SNV Pathogenic
217858 rs863225285 GRCh37: 2:29432655-29432655
GRCh38: 2:29209789-29209789
22 ALK NM_004304.5(ALK):c.3735C>G (p.Phe1245Leu) SNV Pathogenic
375885 rs863225284 GRCh37: 2:29436858-29436858
GRCh38: 2:29213992-29213992
23 ALK NM_004304.5(ALK):c.3824G>T (p.Arg1275Leu) SNV Likely Pathogenic
376365 rs113994087 GRCh37: 2:29432664-29432664
GRCh38: 2:29209798-29209798
24 PTPN11 NM_002834.5(PTPN11):c.227A>G (p.Glu76Gly) SNV Likely Pathogenic
13338 rs121918465 GRCh37: 12:112888211-112888211
GRCh38: 12:112450407-112450407
25 ALK NM_004304.5(ALK):c.3733T>A (p.Phe1245Ile) SNV Likely Pathogenic
217855 rs281864720 GRCh37: 2:29436860-29436860
GRCh38: 2:29213994-29213994
26 ALK NM_004304.5(ALK):c.3520T>C (p.Phe1174Leu) SNV Likely Pathogenic
217849 rs281864719 GRCh37: 2:29443697-29443697
GRCh38: 2:29220831-29220831
27 ALK NM_004304.5(ALK):c.3497T>G (p.Met1166Arg) SNV Likely Pathogenic
376713 rs1057520019 GRCh37: 2:29445228-29445228
GRCh38: 2:29222362-29222362
28 PTPN11 NM_002834.5(PTPN11):c.227A>C (p.Glu76Ala) SNV Likely Pathogenic
13339 rs121918465 GRCh37: 12:112888211-112888211
GRCh38: 12:112450407-112450407
29 ALK NM_004304.5(ALK):c.3733T>C (p.Phe1245Leu) SNV Likely Pathogenic
376712 rs281864720 GRCh37: 2:29436860-29436860
GRCh38: 2:29213994-29213994
30 ALK NM_004304.5(ALK):c.3749T>C (p.Ile1250Thr) SNV Likely Pathogenic
21867 rs113994092 GRCh37: 2:29432739-29432739
GRCh38: 2:29209873-29209873
31 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
32 KIF1B NM_001365951.3(KIF1B):c.3787C>T (p.Pro1263Ser) SNV Likely Pathogenic
4661 rs121908163 GRCh37: 1:10406001-10406001
GRCh38: 1:10345943-10345943
33 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
34 TP53 NM_000546.6(TP53):c.841G>A (p.Asp281Asn) SNV Likely Pathogenic
376586 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
35 PTPN11 NM_002834.5(PTPN11):c.226G>A (p.Glu76Lys) SNV Likely Pathogenic
13336 rs121918464 GRCh37: 12:112888210-112888210
GRCh38: 12:112450406-112450406
36 PTPN11 NM_002834.5(PTPN11):c.215C>T (p.Ala72Val) SNV Likely Pathogenic
41443 rs121918454 GRCh37: 12:112888199-112888199
GRCh38: 12:112450395-112450395
37 TP53 NM_000546.6(TP53):c.842A>G (p.Asp281Gly) SNV Likely Pathogenic
141141 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
38 TP53 NM_000546.6(TP53):c.843C>G (p.Asp281Glu) SNV Likely Pathogenic
376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777
39 ALK NM_004304.5(ALK):c.3383G>C (p.Gly1128Ala) SNV Likely Pathogenic
18084 rs113994088 GRCh37: 2:29445450-29445450
GRCh38: 2:29222584-29222584
40 MYC NM_002467.6(MYC):c.217A>C (p.Thr73Pro) SNV Likely Pathogenic
376458 rs750664148 GRCh37: 8:128750680-128750680
GRCh38: 8:127738434-127738434
41 PIK3CA NM_006218.4(PIK3CA):c.331A>G (p.Lys111Glu) SNV Likely Pathogenic
376482 rs1057519933 GRCh37: 3:178916944-178916944
GRCh38: 3:179199156-179199156
42 ALK NM_004304.5(ALK):c.3522C>G (p.Phe1174Leu) SNV Likely Pathogenic
217852 rs863225281 GRCh37: 2:29443695-29443695
GRCh38: 2:29220829-29220829
43 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu) SNV Likely Pathogenic
376459 rs1057519918 GRCh37: 8:128750636-128750636
GRCh38: 8:127738390-127738390
44 PIK3CA NM_006218.4(PIK3CA):c.333G>C (p.Lys111Asn) SNV Likely Pathogenic
376483 rs1057519934 GRCh37: 3:178916946-178916946
GRCh38: 3:179199158-179199158
45 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile) SNV Likely Pathogenic
376300 rs756091827 GRCh37: 8:128750681-128750681
GRCh38: 8:127738435-127738435
46 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg) SNV Likely Pathogenic
376484 rs1057519935 GRCh37: 3:178916945-178916945
GRCh38: 3:179199157-179199157
47 PTPN11 NM_002834.5(PTPN11):c.215C>A (p.Ala72Asp) SNV Likely Pathogenic
376511 rs121918454 GRCh37: 12:112888199-112888199
GRCh38: 12:112450395-112450395
48 ALK NM_004304.5(ALK):c.3575G>C (p.Arg1192Pro) SNV Likely Pathogenic
18085 rs113994089 GRCh37: 2:29443642-29443642
GRCh38: 2:29220776-29220776
49 SMARCA4 NM_003072.5(SMARCA4):c.535C>T (p.Gln179Ter) SNV Likely Pathogenic
590848 rs1469271544 GRCh37: 19:11097044-11097044
GRCh38: 19:10986368-10986368
50 FGFR1 NM_023110.3(FGFR1):c.1636A>G (p.Asn546Asp) SNV Likely Pathogenic
376429 rs1057519898 GRCh37: 8:38274851-38274851
GRCh38: 8:38417333-38417333

Copy number variations for Neuroblastoma from CNVD:

6 (show top 50) (show all 232)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13319 1 1 124300000 Amplification and loss Neuroblastoma
2 13325 1 1 124300000 Deletion Neuroblastoma
3 13344 1 1 125000000 Copy number Neuroblastoma
4 13349 1 1 125000000 Deletion Neuroblastoma
5 13355 1 1 125000000 Loss Neuroblastoma
6 13407 1 1 2300000 Copy number GNB1 Neuroblastoma
7 13408 1 1 2300000 Copy number SLC35E2A Neuroblastoma
8 13751 1 1 27800000 Loss Neuroblastoma
9 13762 1 1 28000000 Deletion Neuroblastoma
10 13837 1 10001852 10151200 Loss KIF1B Neuroblastoma
11 16476 1 125000000 249250621 Copy number CHD5 Neuroblastoma
12 16477 1 125000000 249250621 Copy number KIF1B Neuroblastoma
13 16597 1 128000000 247249719 Gain Neuroblastoma
14 16598 1 128000000 247249719 Gain Neuroblastoma
15 17283 1 142400000 148000000 Copy number NBPF17P Neuroblastoma
16 17374 1 142600000 147000000 Copy number NBPF1 Neuroblastoma
17 17375 1 142600000 147000000 Copy number NBPF15 Neuroblastoma
18 17376 1 142600000 147000000 Copy number NBPF3 Neuroblastoma
19 18773 1 147305744 147427061 Copy number NBPF1 Neuroblastoma
20 20614 1 153300000 247249719 Gain Neuroblastoma
21 20884 1 155000000 249250621 Gain Neuroblastoma
22 26022 1 195715155 196905060 Gain Neuroblastoma
23 27292 1 206429564 209469901 Gain Neuroblastoma
24 29290 1 2300000 12600000 Loss Neuroblastoma
25 29291 1 2300000 12600000 Loss Neuroblastoma
26 29292 1 2300000 12700000 Loss Neuroblastoma
27 32651 1 3815958 4146056 Amplification DFFB Neuroblastoma
28 32934 1 4056522 10472147 Loss Neuroblastoma
29 33588 1 46500000 51300000 Deletion Neuroblastoma
30 34972 1 5871399 5949729 Loss CHD5 Neuroblastoma
31 36107 1 7200000 16200000 Copy number Neuroblastoma
32 37032 1 84700000 88100000 Deletion Neuroblastoma
33 42798 10 40200000 135534747 Loss Neuroblastoma
34 43291 10 46100000 50100000 Gain Neuroblastoma
35 48305 11 1 10700000 Loss Neuroblastoma
36 48306 11 1 10700000 Loss Neuroblastoma
37 48334 11 1 2800000 Gain Neuroblastoma
38 49040 11 102400000 134452384 Deletion Neuroblastoma
39 49300 11 10515175 10701970 Amplification IRAG1 Neuroblastoma
40 49301 11 10515175 10701970 Amplification RNF141 Neuroblastoma
41 49302 11 10515175 10701970 Amplification LYVE1 Neuroblastoma
42 49698 11 110314720 118319416 Loss Neuroblastoma
43 50154 11 114581997 114912893 Loss CADM1 Neuroblastoma
44 51496 11 12700000 16200000 Copy number SOX6 Neuroblastoma
45 52328 11 16100000 21600000 Deletion Neuroblastoma
46 52785 11 19817525 19848438 Amplification NAV2 Neuroblastoma
47 52827 11 2043796 2201921 Amplification IGF2 Neuroblastoma
48 52828 11 2043796 2201921 Amplification INS Neuroblastoma
49 52829 11 2043796 2201921 Amplification TH Neuroblastoma
50 53355 11 2800000 10700000 Duplication LMO1 Neuroblastoma

Expression for Neuroblastoma

Search GEO for disease gene expression data for Neuroblastoma.

Pathways for Neuroblastoma

GO Terms for Neuroblastoma

Biological processes related to Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of vascular endothelial growth factor production GO:1904046 8.62 MIR34A MIR17

Sources for Neuroblastoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....